Terms: = Small Cell Lung Cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Staging
17 results:
1. Establishment and Validation of Nomogram Model Integrated With Inflammation-Based Factors for the Prognosis of Advanced Non-small cell lung cancer.
Huang Z; Xing S; Zhu Y; Qu Y; Jiang L; Sheng J; Wang Q; Xu S; Xue N
Technol Cancer Res Treat; 2020; 19():1533033820971605. PubMed ID: 33191854
[TBL] [Abstract] [Full Text] [Related]
2. Molecular analysis in cytological samples obtained by endobronchial or oesophageal ultrasound guided needle aspiration in non-small cell lung cancer.
Centeno C; Serra Mitja P; Avila M; Carcereny E; Muñoz-Mármol AM; Moran T; Castellà E; Sanz-Santos J; García Olivé I; Ramirez Serrano JL; Rosell Gratacos A; Andreo García F
Pulmonology; 2022; 28(1):28-33. PubMed ID: 32507497
[TBL] [Abstract] [Full Text] [Related]
3. staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.
Antoun S; Morel H; Souquet PJ; Surmont V; Planchard D; Bonnetain F; Foucher P; Egenod T; Krakowski I; Gaudin H; Debieuvre D
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):782-793. PubMed ID: 30932365
[TBL] [Abstract] [Full Text] [Related]
4. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
5. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract] [Full Text] [Related]
6. [Inhibitor of apoptosis in lung cancer Livin perioperative clinical research].
Wang LN; Mou J; Zhang YB; Dong P; Diao X; Wang SY; Chen H; Liu YF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Sep; 26(9):889-90. PubMed ID: 20815986
[TBL] [Abstract] [Full Text] [Related]
7. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer.
Zhu ZH; Sun BY; Ma Y; Shao JY; Long H; Zhang X; Fu JH; Zhang LJ; Su XD; Wu QL; Ling P; Chen M; Xie ZM; Hu Y; Rong TH
J Clin Oncol; 2009 Mar; 27(7):1091-9. PubMed ID: 19188679
[TBL] [Abstract] [Full Text] [Related]
8. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract] [Full Text] [Related]
10. her-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P
Cancer; 2002 May; 94(10):2669-74. PubMed ID: 12173335
[TBL] [Abstract] [Full Text] [Related]
11. Towards a biological staging model for operable non-small cell lung cancer.
O'Byrne KJ; Cox G; Swinson D; Richardson D; Edwards JG; Lolljee J; Andi A; Koukourakis MI; Giatromanolaki A; Gatter K; Harris AL; Waller D; Jones JL
Lung Cancer; 2001 Dec; 34 Suppl 2():S83-9. PubMed ID: 11720747
[TBL] [Abstract] [Full Text] [Related]
12. Predicting the sites of metastases from lung cancer using molecular biologic markers.
D'Amico TA; Aloia TA; Moore MB; Conlon DH; Herndon JE; Kinch MS; Harpole DH
Ann Thorac Surg; 2001 Oct; 72(4):1144-8. PubMed ID: 11603427
[TBL] [Abstract] [Full Text] [Related]
13. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract] [Full Text] [Related]
14. Genetic evolutionary staging of early non-small cell lung cancer: the P53 --> her-2/neu --> ras sequence.
Shackney SE; Smith CA; Pollice A; Levitt M; Magovern JA; Wiechmann RJ; Silverman J; Sweeney L; Landreneau RJ
J Thorac Cardiovasc Surg; 1999 Aug; 118(2):259-67. PubMed ID: 10424999
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
Fontanini G; De Laurentiis M; Vignati S; Chinè S; Lucchi M; Silvestri V; Mussi A; De Placido S; Tortora G; Bianco AR; Gullick W; Angeletti CA; Bevilacqua G; Ciardiello F
Clin Cancer Res; 1998 Jan; 4(1):241-9. PubMed ID: 9516978
[TBL] [Abstract] [Full Text] [Related]
16. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
[TBL] [Abstract] [Full Text] [Related]
17. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.
Harpole DH; Herndon JE; Wolfe WG; Iglehart JD; Marks JR
Cancer Res; 1995 Jan; 55(1):51-6. PubMed ID: 7805040
[TBL] [Abstract] [Full Text] [Related]
